Asthma pharmacogenetics and the development of genetic profiles for personalized medicine

Pharmacogenomics and Personalized Medicine

Volumn 8, Issue , 2015, Pages 9-22

  Ortega, Victor E ^a   Meyers, Deborah A ^a   Bleecker, Eugene R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Asthma; Genome wide association study; Pharmacogenetics; Response heterogeneity; Single nucleotide polymorphism

Indexed keywords

ATRELEUTON; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; DUPILUMAB; FENOTEROL; FLUNISOLIDE; FLUTICASONE; FORMOTEROL; GLUCOCORTICOID; INDACATEROL; IPRATROPIUM BROMIDE; ISOPRENALINE; LEUKOTRIENE RECEPTOR AFFECTING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LEVALBUTEROL; LIPOXYGENASE INHIBITOR; MONTELUKAST; PEPTIDOLEUKOTRIENE; PITRAKINRA; PLACEBO; SALBUTAMOL; SALMETEROL; TRIAMCINOLONE; VILANTEROL; ZILEUTON;

ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TARGETING; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HERITABILITY; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84921754825     PISSN: None     EISSN: 11787066     Source Type: Journal    
DOI: 10.2147/PGPM.S52846     Document Type: Article

References (90)

1. [No authors listed]. Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. Am J Respir Crit Care Med. 2000;162(6):2341–2351.
2. Chan MT, Leung DY, Szefer SJ, Spahn JD. Diffcult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol. 1998;101(5):594–601.
3. Salpeter SR, Buckley NS, Ormiston TM, Salpeter EE. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006;144(12):904–912.
4. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306(6884):1034–1037.
5. Nelson HS, Weiss ST, Bleecker ER, Yancey S W, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129(1):15–26.
6. Meyers DA, Bleecker ER, Holloway J W, Holgate ST. Asthma genetics and personalised medicine. Lancet Respir Med. 2014;2(5):405–415.
7. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull. 2000;56(4):1054–1070.
8. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter-and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics. 1998;8(4):283–289.
9. Israel E, Chinchilli VM, Ford JG, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratifed, randomised, placebo-controlled cross-over trial. Lancet. 2004;364(9444):1505–1512.
10. Li X, Hawkins GA, Ampleford EJ, et al. Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients. J Allergy Clin Immunol. 2013;132(2):313–320. e315.
11. Li X, Howard TD, Moore WC, et al. Importance of hedgehog interacting protein and other lung function genes in asthma. J Allergy Clin Immunol. 2011;127(6):1457–1465.
12. Rosell R, Bivona TG, Karachaliou N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet. 2013;382(9893): 720–731.
13. Ramsey B W, Davies J, McElvaney NG, et al. A CFTR potentiator in patients with cystic fbrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663–1672.
14. Peters S P, Anthonisen N, Castro M, et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med. 2007;356(20):2027–2039.
15. Sorkness CA, Lemanske RF Jr, Mauger DT, et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. J Allergy Clin Immunol. 2007;119(1):64–72.
16. Szefer SJ, Phillips BR, Martinez FD, et al. Characterization of within-subject responses to futicasone and montelukast in childhood asthma. J Allergy Clin Immunol. 2005;115(2):233–242.
17. Tantisira KG, Lake S, Silverman ES, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004;13(13):1353–1359.
18. Hawkins GA, Lazarus R, Smith RS, et al. The glucocorticoid receptor heterocomplex gene STIP1 is associated with improved lung function in asthmatic subjects treated with inhaled corticosteroids. J Allergy Clin Immunol. 2009;123(6):1376–1383. e1377.
19. Tantisira KG, Small KM, Litonjua AA, Weiss ST, Liggett SB. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet. 2005;14(12): 1671–1677.
20. Kim SH, Ye YM, Lee HY, Sin HJ, Park HS. Combined pharmacogenetic effect of ADCY9 and ADRB2 gene polymorphisms on the broncho-dilator response to inhaled combination therapy. J Clin Pharm Ther. 2011;36(3):399–405.
21. Tantisira KG, Hwang ES, Raby BA, et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A. 2004;101(52):18099–18104.
22. Ye YM, Lee HY, Kim SH, et al. Pharmacogenetic study of the effects of NK2R G231E G.A and TBX21 H33Q C.G polymorphisms on asthma control with inhaled corticosteroid treatment. J Clin Pharm Ther. 2009;34(6):693–701.
23. Stockmann C, Fassl B, Gaedigk R, et al. Fluticasone propionate pharmacogenetics: CYP3A4*22 polymorphism and pediatric asthma control. J Pediatr. 2013;162(6):1222–1227. e1–e2.
24. Tantisira KG, Lasky-Su J, Harada M, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med. 2011;365(13):1173–1183.
25. Hosking L, Bleecker E, Ghosh S, et al. GLCCI1 rs37973 does not infuence treatment response to inhaled corticosteroids in white subjects with asthma. J Allergy Clin Immunol. 2014;133(2):587–589.
26. Tantisira KG, Damask A, Szefer SJ, et al. Genome-wide association identifes the T gene as a novel asthma pharmacogenetic locus. Am J Respir Crit Care Med. 2012;185(12):1286–1291.
27. Drazen JM, Yandava CN, Dube L, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999;22(2):168–170.
28. Telleria JJ, Blanco-Quiros A, Varillas D, et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med. 2008;102(6):857–861.
29. Klotsman M, York T P, Pillai SG, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics. 2007;17(3):189–196.
30. Lima JJ, Zhang S, Grant A, et al. Infuence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med. 2006;173(4):379–385.
31. Tantisira KG, Lima J, Sylvia J, Klanderman B, Weiss ST. 5-lipoxygenase pharmacogenetics in asthma: overlap with Cys-leukotriene receptor antagonist loci. Pharmacogenet Genomics. 2009;19(3):244–247.
32. Mougey E, Lang JE, Allayee H, et al. ALOX5 polymorphism associates with increased leukotriene production and reduced lung function and asthma control in children with poorly controlled asthma. Clin Exp Allerg y. 2013;43(5):512–520.
33. Mougey EB, Feng H, Castro M, Irvin CG, Lima JJ. Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response. Pharmacogenet Genomics. 2009;19(2):129–138.
34. Kim KA, Lee HM, Joo HJ, Park IB, Park JY. Effects of polymorphisms of the SLCO2B1 transporter gene on the pharmacokinetics of montelu-kast in humans. J Clin Pharmacol. 2013;53(11):1186–1193.
35. Tapaninen T, Karonen T, Backman JT, Neuvonen PJ, Niemi M. SLCO2B1 c.935G.A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren. Pharmacogenet Genomics. 2013;23(1):19–24.
36. Grainger J, Woodman K, Pearce N, et al. Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study. Thorax. 1991;46(2):105–111.
37. Crane J, Pearce N, Burgess C, Jackson R, Beasley R. End of New Zealand asthma epidemic. Lancet. 1995;345(8955):984–985.
38. Pearce N, Grainger J, Atkinson M, et al. Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81. Thorax. 1990;45(3):170–175.
39. Pearce N, Burgess C, Crane J, Beasley R. Fenoterol, asthma deaths, and asthma severity. Chest. 1997;112(4):1148–1150.
40. Stolley PD. Asthma mortality. Why the United States was spared an epidemic of deaths due to asthma. Am Rev Respir Dis. 1972;105(6):883–890.
41. US Food and Drug Administration. FDA Drug Safety Communication: FDA requires post-market safety trials for long-acting beta-agonists (LABAs). 2011. Available from: http://www.fda.gov/Drugs/ DrugSafety/ucm251512.htm. Accessed July 10, 2012.
42. Peters S P, Prenner BM, Mezzanotte WS, Martin P, O’Brien CD. Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients. Allergy Asthma Proc. 2008;29(5):499–516.
43. Sears MR, Ottosson A, Radner F, Suissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J. 2009;33(1):21–32.
44. Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med. 2011;364(26):2473–2475.
45. Hawkins GA, Tantisira K, Meyers DA, et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med. 2006;174(10):1101–1109.
46. Ortega VE, Hawkins GA, Moore WC, et al. Effect of rare genetic variants in ADRB2 on risk of severe exacerbations and symptom control during longacting beta agonist treatment in a multiethnic asthma population. Lancet Respir Med. 2014;2(3):204–213.
47. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A. 2000;97(19):10483–10488.
48. Choudhry S, Ung N, Avila PC, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med. 2005;171(6):563–570.
49. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther. 1999;65(5):519–525.
50. Taylor DR, Drazen JM, Herbison G P, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 2000;55(9):762–767.
51. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000;162(1):75–80.
52. Bousquet J, Bousquet PJ, Godard P, Daures J P. The public health implications of asthma. Bull World Health Organ. 2005;83(7):548–554.
53. Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic receptor polymorphism on response to lon-gacting beta2 agonist in asthma (LARGE trial): a genotype-stratifed, randomised, placebo-controlled, crossover trial. Lancet. 2009;374(9703):1754–1764.
54. Bleecker ER, Nelson HS, Kraft M, et al. Beta2-receptor polymorphisms in patients receiving salmeterol with or without futicasone propionate. Am J Respir Crit Care Med. 2010;181(7):676–687.
55. Green SA, Cole G, Jacinto M, Innis M, Liggett SB. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem. 1993;268(31):23116–23121.
56. Green SA, Rathz DA, Schuster AJ, Liggett SB. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol. 2001;421(3):141–147.
57. Thomsen M, Nordestgaard BG, Sethi AA, Tybjaerg-Hansen A, Dahl M. beta2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies. Eur Respir J. 2012;39(3):558–566.
58. Poon AH, Tantisira KG, Litonjua AA, et al. Association of corti-cotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma. Pharmacogenet Genomics. 2008;18(5):373–382.
59. Drake KA, Torgerson DG, Gignoux CR, et al. A genome-wide association study of bronchodilator response in Latinos implicates rare variants. J Allergy Clin Immunol. 2014;133(2):370–378.
60. Litonjua AA, Lasky-Su J, Schneiter K, et al. ARG1 is a novel broncho-dilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med. 2008;178(7):688–694.
61. Vonk JM, Postma DS, Maarsingh H, Bruinenberg M, Koppelman GH, Meurs H. Arginase 1 and arginase 2 variations associate with asthma, asthma severity and beta2 agonist and steroid response. Pharmacogenet Genomics. 2010;20(3):179–186.
62. Duan QL, Gaume BR, Hawkins GA, et al. Regulatory haplotypes in ARG1 are associated with altered bronchodilator response. Am J Respir Crit Care Med. 2011;183(4):449–454.
63. Iordanidou M, Paraskakis E, Tavridou A, Paschou P, Chatzimichael A, Manolopoulos VG. G894T polymorphism of eNOS gene is a predictor of response to combination of inhaled corticosteroids with long-lasting beta2-agonists in asthmatic children. Pharmacogenomics. 2012;13(12): 1363–1372.
64. Himes BE, Jiang X, Hu R, et al. Genome-wide association analysis in asthma subjects identifes SPATS2L as a novel bronchodilator response gene. PLoS Genet. 2012;8(7):e1002824.
65. Duan QL, Lasky-Su J, Himes BE, et al. A genome-wide association study of bronchodilator response in asthmatics. Pharmacogenomics J. 2014;14(1):41–47.
66. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013;368(26): 2455–2466.
67. Slager RE, Otulana BA, Hawkins GA, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol. 2012;130(2):516–522. e514.
68. Ortega VE, Meyers DA. Pharmacogenetics: Implications of race and ethnicity on defning genetic profles for personalized medicine. J Allergy Clin Immunol. 2014;133(1):16–26.
69. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, et al. An integrated map of genetic variation from 1,092 human genomes. Nature. 2012;491(7422):56–65.
70. Ortega VE, Wechsler ME. Asthma pharmacogenetics: responding to the call for a personalized approach. Curr Opin Allergy Clin Immunol. 2013;13(4):399–409.
71. Choudhry S, Que LG, Yang Z, et al. GSNO reductase and beta2-adrenergic receptor gene-gene interaction: bronchodilator responsiveness to albuterol. Pharmacogenet Genomics. 2010;20(6):351–358.
72. Himes BE, Wu AC, Duan QL, et al. Predicting response to short-acting bronchodilator medication using Bayesian networks. Pharmacogenomics. 2009;10(9):1393–1412.
73. Duan QL, Du R, Lasky-Su J, et al. A polymorphism in the thyroid hormone receptor gene is associated with bronchodilator response in asthmatics. Pharmacogenomics J. 2013;13(2):130–136.
74. Begin P, Nadeau KC. Epigenetic regulation of asthma and allergic disease. Allergy Asthma Clin Immunol. 2014;10(1):27.
75. Michel S, Busato F, Genuneit J, et al. Farm exposure and time trends in early childhood may infuence DNA methylation in genes related to asthma and allergy. Allergy. 2013;68(3):355–364.
76. Soto-Ramirez N, Arshad SH, Holloway J W, et al. The interaction of genetic variants and DNA methylation of the interleukin-4 receptor gene increase the risk of asthma at age 18 years. Clin Epigenetics. 2013;5(1):1.
77. Gaffn JM, Raby BA, Petty CR, et al. beta-2 adrenergic receptor gene methylation is associated with decreased asthma severity in inner-city schoolchildren: asthma and rhinitis. Clin Exp Allergy. 2014;44(5):681–689.
78. Fu A, Leaderer B P, Gent JF, Leaderer D, Zhu Y. An environmental epigenetic study of ADRB2 5′-UTR methylation and childhood asthma severity. Clin Exp Allergy. 2012;42(11):1575–1581.
79. Zheng SL, Sun J, Wiklund F, et al. Cumulative association of fve genetic variants with prostate cancer. N Engl J Med. 2008;358(9):910–919.
80. Thanassoulis G, Peloso GM, Pencina MJ, et al. A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium: the Framingham Heart Study. Circ Cardiovasc Genet. 2012;5(1):113–121.
81. Aronson SJ, Clark EH, Varugheese M, Baxter S, Babb LJ, Rehm HL. Communicating new knowledge on previously reported genetic variants. Genet Med. April 5, 2012. [Epub ahead of print.]
82. York T P, Vargas-Irwin C, Anderson WH, van den Oord EJ. Asthma pharmacogenetic study using fnite mixture models to handle drug-response heterogeneity. Pharmacogenomics. 2009;10(5):753–767.
83. Ortega VE, Hawkins GA, Peters S P, Bleecker ER. Pharmacogenetics of the beta 2-adrenergic receptor gene. Immunol Allergy Clin North Am. 2007;27(4):665–684; vii.
84. Tsuji S. Genetics of neurodegenerative diseases: insights from high-throughput resequencing. Hum Mol Genet. 2010;19(R1):R65–R70.
85. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 1997;100(12):3184–3188.
86. Wechsler ME, Lehman E, Lazarus SC, et al. Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173(5):519–526.
87. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet. 2007;370(9605):2118–2125.
88. Bleecker ER, Yancey S W, Baitinger LA, et al. Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent asthma. J Allergy Clin Immunol. 2006;118(4):809–816.
89. Lee DK, Currie G P, Hall I P, Lima JJ, Lipworth BJ. The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br J Clin Pharmacol. 2004;57(1):68–75.
90. Lipworth BJ, Basu K, Donald H P, et al. Tailored second-line therapy in asthmatic children with the Arg16 genotype. Clin Sci (Lond). 2013;124(8):521–528.